(Finance) – The European Commission has approvedunder the EU Merger Regulation, theacquisition of the joint control of Imedica Pharma by Impilo, both Swedish, and KKRof the United States. The transaction primarily involves the commercialization of rare disease medicines and specialty care products.
The Commission concluded that the notified transaction would not raise competition concernsgiven the limited market positions of the companies resulting from the proposed transaction. The notified transaction was examined under the simplified merger review procedure.